Literature DB >> 7352751

(E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis.

P C Maudgal, E De Clercq, J Descamps, L Missotten, P De Somer, R Busson, H Vanderhaeghe, G Verhelst, R T Walker, A S Jones.   

Abstract

IDU (5-iodo-2'-deoxyuridine), BVDU [(E)-5-(2-bromovinyl)-2'-deoxyuridine] and placebo ointments were studied for their effects on experimental herpes simplex (type 1) keratoconjuncitivitis in rabbits. When treatment was begun 65 h after virus inoculation, both BVDU and IDU prevented development of keratitis. Both BVDU and IDU were also effective in suppressing the severity of conjunctivitis, and in this respect, BVDU proved significantly better than IDU. When treatment was started 110 h after virus inoculation, BVDU proved significantly better than IDU in promoting healing of established keratitis.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7352751      PMCID： PMC283717          DOI： 10.1128/AAC.17.1.8

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine.

Authors:  H E KAUFMAN
Journal:  Proc Soc Exp Biol Med       Date:  1962-02

2.  Phosphonoacetic acid in the treatment of experimental ocular herpes simplex infections.

Authors:  R F Meyer; E D Varnell; H E Kaufman
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

3.  Effect of 9-(2-hydroxyethoxymethyl)guanine on herpesvirus-induced keratitis and iritis in rabbits.

Authors:  H E Kaufman; E D Varnell; Y M Centifanto; S D Rheinstrom
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

4.  Acyclic antimetabolite therapy of experimental herpes simplex keratitis.

Authors:  D Pavan-Langston; R Campbell; J Lass
Journal:  Am J Ophthalmol       Date:  1978-11       Impact factor: 5.258

5.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

6.  Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice.

Authors:  J Descamps; E De Clercq; P J Barr; A S Jones; R T Walker; P F Torrence; D Shugar
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

7.  THERAPEUTIC ANTIVIRAL ACTION OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE IN HERPES SIMPLEX KERATITIS.

Authors:  H E KAUFMAN; C HEIDELBERGER
Journal:  Science       Date:  1964-08-07       Impact factor: 47.728

8.  Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers.

Authors:  B R Jones; D J Coster; P N Fison; G M Thompson; L M Cobo; M G Falcon
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321
  8 in total
  14 in total

1.  Crystal and molecular structure of (E)-5-(2-bromovinyl-2'-deoxyuridine).

Authors:  L Párkányi; A Kálmán; T Kovács; A Szabolcs; L Otvös
Journal:  Nucleic Acids Res       Date:  1983-11-25       Impact factor: 16.971

Review 2.  Recurrent herpes simplex: the outlook for systemic antiviral agents.

Authors:  H J Field; P Wildy
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-06

3.  Influence of (E)-5-(2-bromovinyl)-2'-deoxyuridine on corneal epithelium healing.

Authors:  P C Maudgal; N De Kimpe; E De Clercq; J Descamps; L Missotten; A Geysen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

4.  Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.

Authors:  E de Clercq; H Degreef; J Wildiers; G de Jonge; A Drochmans; J Descamps; P de Somer
Journal:  Br Med J       Date:  1980-11-01

5.  Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.

Authors:  E de Clercq; Z X Zhang; I S Sim
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

6.  Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on proliferation of human fibroblasts, peripheral blood mononuclear cells, and granulocyte-monocyte progenitor cells in vitro.

Authors:  A E Wittek; P S Cohen; A M Arvin; S D Smith; C M Koropchak; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

7.  Randomised double-blind trial of bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration.

Authors:  W J Power; A Benedict-Smith; M Hillery; K Brady; L M Collum
Journal:  Br J Ophthalmol       Date:  1991-11       Impact factor: 4.638

8.  Corneal epithelial dysplasia after trifluridine use.

Authors:  P C Maudgal; B Van Damme; L Missotten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

9.  Modified polynucleotides. VI. Properties of a synthetic DNA containing the anti-herpes agent (E)-5-(2-bromovinyl)-2'-deoxyuridine.

Authors:  J Sági; A Czuppon; M Kajtár; A Szabolcs; A Szemzö; L Otvös
Journal:  Nucleic Acids Res       Date:  1982-10-11       Impact factor: 16.971

10.  Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes simplex keratitis.

Authors:  P C Maudgal; L Missotten; E De Clercq; J Descamps; E De Meuter
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.